Drugs /

modified vaccinia virus ankara vaccine expressing p53

Back to Drugs List

Overview

NCI Definition [1]:
A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with MVA vaccine expressing p53, the expressed p53 may stimulate the host immune system to mount a p53-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing p53, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain and is incapable of virion assembly. The p53 gene, a tumor suppressor gene, is mutated in many cancer cell types.

Clinical Trials

View Clinical Trials for modified vaccinia virus ankara vaccine expressing p53

Modified vaccinia virus ankara vaccine expressing p53 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating modified vaccinia virus ankara vaccine expressing p53, 2 are phase 1 (1 open) and 1 is phase 2 (1 open).

TP53 Overexpression, TP53 Loss, and TP53 Mutation are the most frequent biomarker inclusion criteria for modified vaccinia virus ankara vaccine expressing p53 clinical trials.

Fallopian tube carcinoma, ovarian carcinoma, and primary peritoneal carcinoma are the most common diseases being investigated in modified vaccinia virus ankara vaccine expressing p53 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Modified Vaccinia Virus Ankara Vaccine Expressing P53
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Modified Vaccinia Virus Ankara Vaccine Expressing P53
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating modified vaccinia virus ankara vaccine expressing p53 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
modified vaccinia virus ankara vaccine expressing p53, mva-p53, p53-mva vaccine, p53mva, mvap53 vaccine, mva-p53 vaccine, mva-p53 vaccine, mvap53 vaccine
NCIT ID [1]:
C116868

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.